You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
國藥中生副總裁:國藥新冠滅活疫苗有望在孕婦中大面積推廣
阿思達克 05-14 07:59
國藥集團中國生物副總裁、首席科學家張雲濤在新冠滅活疫苗三期臨床研究情況介紹的發言中提到,國藥中生新冠疫苗三期臨床研究中,接種期間發生妊娠事件13例,其中安慰劑組8例,疫苗組5例,妊娠婦女目前產檢一切正常。

2021年5月,第一例嬰兒出生,健康狀況良好。張雲濤表示,該案例說明國藥中生新冠滅活疫苗未來有望在孕婦中大面積推廣。國藥集團中國生物在國內的臨床研究,也在持續追蹤這部份人群。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account